Effects of Lactobacillus Casei Shirota, Bifidobacterium Breve, and Oligofructose-enriched Inulin on Colonic Nitrogen-protein Metabolism in Healthy Humans
Overview
Physiology
Authors
Affiliations
Pre- and/or probiotics can cause changes in the ecological balance of intestinal microbiota and hence influence microbial metabolic activities. In the present study, the influence of oligofructose-enriched inulin (OF-IN), Lactobacillus casei Shirota, and Bifidobacterium breve Yakult on the colonic fate of NH3 and p-cresol was investigated. A randomized, placebo-controlled, crossover study was performed in 20 healthy volunteers to evaluate the influence of short- and long-term administration of OF-IN, L. casei Shirota, B. breve Yakult, and the synbiotic L. casei Shirota + OF-IN. The lactose[15N,15N]ureide biomarker was used to study the colonic fate of NH3. Urine and fecal samples were analyzed for 15N content by combustion-isotope ratio mass spectrometery and for p-cresol content by gas chromatography-mass spectrometry. RT-PCR was applied to determine the levels of total bifidobacteria. Both short- and long-term administration of OF-IN resulted in significantly decreased urinary p-cresol and 15N content. The reduction of urinary 15N excretion after short-term OF-IN intake was accompanied by a significant increase in the 15N content of the fecal bacterial fraction. However, this effect was not observed after long-term OF-IN intake. In addition, RT-PCR results indicated a significant increase in total fecal bifidobacteria after long-term OF-IN intake. Long-term L. casei Shirota and B. breve Yakult intake showed a tendency to decrease urinary 15N excretion, whereas a significant decrease was noted in p-cresol excretion. In conclusion, dietary addition of OF-IN, L. casei Shirota, and B. breve Yakult results in a favorable effect on colonic NH3 and p-cresol metabolism, which, in the case of OF-IN, was accompanied by an increase in total fecal bifidobacteria.
The Legalome: Microbiology, Omics and Criminal Justice.
Logan A, Mishra P, Prescott S Microb Biotechnol. 2025; 18(3):e70129.
PMID: 40072296 PMC: 11898878. DOI: 10.1111/1751-7915.70129.
Lessard-Lord J, Roussel C, Lupien-Meilleur J, Genereux P, Richard V, Guay V NPJ Biofilms Microbiomes. 2024; 10(1):18.
PMID: 38448452 PMC: 10918075. DOI: 10.1038/s41522-024-00493-w.
Sanchez M, Herraiz A, Tigre S, Llama-Palacios A, Hernandez M, Ciudad M Nutrients. 2023; 15(24).
PMID: 38140334 PMC: 10745619. DOI: 10.3390/nu15245077.
Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease.
Pandey H, Jain D, Tang D, Wong S, Lal D Intest Res. 2023; 22(1):15-43.
PMID: 37935653 PMC: 10850697. DOI: 10.5217/ir.2023.00080.
Li S, Xu K, Cheng Y, Chen L, Yi A, Xiao Z Front Microbiol. 2023; 14:1188455.
PMID: 37389342 PMC: 10303177. DOI: 10.3389/fmicb.2023.1188455.